A high sIL-2R/ferritin ratio is a useful marker for the diagnosis of lymphoma-associated hemophagocytic syndrome

Abstract

Lymphoma-associated hemophagocytic syndrome (LAHS), which is the major subtype of adult-onset secondary hemophagocytic lymphohistiocytosis (HLH), has a poor outcome. Although the early diagnosis and treatment of LAHS contributes to a better outcome, the lack of mass formation and the absence of distinct lymph node enlargement often delay the diagnosis of underlying lymphoma. A recent study, which statistically analyzed HLH cases in the literature, showed that the serum soluble interleukin-2 receptor (sIL-2R)/ferritin ratio could be used as a marker to diagnosis of LAHS. To verify this finding, we retrospectively analyzed the laboratory findings of 21 patients with HLH (10 benign disease-associated HLH and 11 LAHS). No significant differences were observed in the levels of LDH or CRP levels. The mean sIL-2R levels (units per milliliter) were significantly higher in the LAHS group (4,176 vs. 13,451, p = 0.0031), and ferritin levels (nanogram per milliliter) were higher in the benign disease-associated HLH group (20,462 vs. 2,561, p = 0.0031). Consequently, the mean serum sIL-2R/ferritin ratio of patients with LAHS was markedly higher than that of patients with benign disease-associated HLH (0.66 vs. 8.56, p = 0.0004). Thus, the results of this study demonstrated that the serum sIL-2R/ferritin ratio is a very useful marker for diagnosing of LAHS, which was further supported by clinical case analysis. Further studies to clarify the pathophysiology of secondary HLH caused by various triggers are needed.

Introduction

Hemophagocytic lymphohistiocytosis (HLH) is a clinicopathological entity characterized by the increased proliferation of benign macrophages that phagocytose blood cells throughout the reticuloendothelial system [1]. HLH has been classified into two distinct forms: primary or familial HLH and secondary HLH. Secondary HLH is an etiologically heterogeneous entity that has been associated with infections, autoimmune disorders, drugs, and malignant disease, typically malignant lymphoma [2–4]. Lymphoma-associated hemophagocytic syndrome (LAHS) is a subtype that accounts for approximately 40 % of adult-onset secondary HLH and has a poor outcome [5]. Although the early diagnosis of underlying conditions, especially malignant lymphoma, leads to a better outcome, the diagnosis of LAHS is often difficult because of the frequent lack of mass formation and absence of distinct lymph node enlargement, which results in the development of progressive disease with an unfavorable prognosis. Tabata et al. reviewed Japanese patients in the literature and proposed that the serum soluble interleukin-2 receptor (sIL-2R)/ferritin ratio could be a useful marker for predicting underlying malignant lymphoma in HLH patients [6]. Here, we evaluated the serum sIL-2R/ferritin ratios of HLH patients in our institution to confirm its utility in differentiating LAHS from other reactive HLH.

Methods

Patients and methods

We retrospectively collected data on 21 patients who were diagnosed with HLH (benign disease-associated HLH and LAHS) between 2000 and 2011 at the Kumamoto City Hospital. Data collected on each patient included age, presumed etiology, presence or absence of splenomegaly, white blood cell (WBC), absolute neutrophil count (ANC), hemoglobin (Hb), platelet (PLT), aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), triglycerides (TG), fibrinogen (Fib), C-reactive protein (CRP), sIL-2R, ferritin, nuclear cell count (NCC), and percentage of macrophages in the bone marrow. HLH was diagnosed according to the HLH-2004 diagnostic guidelines [7]. Five of the following eight criteria had to be fulfilled: (1) fever; (2) splenomegaly; (3) cytopenia affecting at least two of three lineages in the peripheral blood; (4) hypertriglyceridemia (triglycerides of ≥265 mg/dl) and/or hypofibrinogenemia (fibrinogen of ≤150 mg/dl); (5) hemophagocytosis in the bone marrow, spleen, or lymph nodes; (6) low or absent NK cell activity; (7) hyperferritinemia (ferritin of ≥500 μg/l); and (8) high levels of sIL-2R (≥2,400 U/ml). The diagnosis of malignant lymphoma was made according to the 2008 WHO classification [8]. We compared the laboratory findings (WBC, ANC, Hb, PLT, AST, ALT, LDH, CRP, ferritin, sIL-2R, and sIL-2R/ferritin ratio) of the benign disease-associated HLH group with those of the LAHS group. The nonparametric Mann–Whitney U test was used to compare the values of the two groups. In all tests, a p value of <0.05 was considered significant.

Results

Clinical features

A total of 21 patients were included in this analysis. The clinical characteristics of these patients are described in Tables 1, 2, 3, and 4. Benign disease-associated HLH was diagnosed in 10 patients (case B1-10 in Tables 1 and 2; benign disease-associated HLH group), and LAHS in 11 patients (case L1-11 in Tables 3 and 4; LAHS group).

Table 1.

Clinical characteristics of patients with benign disease-associated HLH

Case	Age	Sex	Cause	WBC (/μl)	ANC (/μl)	Hb (g/dl)	PLT (/μl)	AST (U/l)	ALT (U/l)	LDH (/UNL)	TG (mg/dl)	Fib (mg/dl)	CRP (mg/dl)
B1	17	M	Unknown	2,400	384	11.0	6.5	2,090	2,590	11.8	n.t.	198	0.5
B2	62	F	Erythema exsudativum multiforme	3,400	1,700	12.7	10.5	368	307	3.1	199	162	0.4
B3	52	M	Pneumonia	2,400	1,176	13.5	4.2	427	328	4.2	n.t.	415	19.9
B4	31	M	CMV	3,500	1,820	13.6	4.2	91	61	5.0	n.t.	478	23.6
B5	50	F	Unknown	600	189	11.2	5.4	6,300	3,400	32.3	157	134	7.4
B6	50	M	EBV	5,300	2,730	13.8	10.8	203	353	2.2	n.t.	333	3.1
B7	41	M	Malaria	4,100	1,353	10.4	7.6	60	73	2.0	729	574	14.2
B8	33	M	Malaria	2,600	1,300	10.7	4.3	40	74	1.4	310	456	19.8
B9	68	F	AOSD	2,400	984	9.2	13.9	57	37	1.4	123	276	1.2
B10	32	F	AOSD	13,800	12,765	11.6	4.3	1,978	1,820	17.5	239	188	3.8

ANC absolute neutrophil count, TG triglyceride, Fib fibrinogen, CMV cytomegalovirus, EBV Epstein–Barr virus, AOSD adult-onset Still’s disease, UNL upper normal limit, n.t. not tested

Table 2.

Clinical characteristics of patients with benign disease-associated HLH

Case	Splenomegaly	Hemophagocytosis (bone marrow)	NCC (/μl)	Histiocyte (%)	HLH-2004	sIL2R (U/ml)	Ferritin (ng/ml)	sIL2R/ferritin
B1	+	+	65.0 × 104	0.6	5 (8)	2,162	26,798	0.08
B2	+	+	3.0 × 104	1.6	5 (8)	2,704	11,775	0.22
B3	+	+	8.6 × 104	6.0	5 (8)	8,657	29,577	0.29
B4	+	+	7.0 × 104	2.6	5 (8)	3,660	11,174	0.32
B5	+	+	2.1 × 104	9.6	7 (8)	4,028	6,865	0.58
B6	+	+	3.0 × 104	1.0	5 (8)	2,416	882	2.73
B7	+	n.t.	n.t.	n.t.	5 (8)	2,563	6,947	0.37
B8	+	n.t.	n.t.	n.t.	5 (8)	3,222	2,746	1.17
B9	+	+	0.9 × 104	3.0	5 (8)	6,078	7,852	0.77
B10	+	+	6.0 × 104	3.4	5 (8)	6,271	100,000	0.06

NCC nuclear cell count, n.t. not tested

Table 3.

Clinical characteristics of patients with LAHS

Case	Age	Sex	Cause	Diagnosed site	Bone marrow invasion	Stage	WBC (/μl)	ANC (/μl)	Hb (g/dl)	PLT (/μl)	AST (U/l)	ALT (U/l)	LDH (/UNL)	Fib (mg/dl)	TG (mg/dl)	CRP (mg/dl)
L1	73	M	IVLBCL	Bone marrow	+	IVB	4,100	3,342	10.8	7.6	25	19	1.7	213	n.t.	1.9
L2	67	M	IVLBCL	Autopsy	+	IVB	8,200	6,560	8.4	12.3	45	19	3.5	301	159	13.9
L3	98	F	DLBCL, NOS	Lymph node	Not detected	IVB	3,800	2,413	8.9	13.4	34	9	6.7	n.t.	n.t.	29.3
L4	74	F	IVLBCL	Bone marrow	+	IVB	4,200	1,953	7.6	16.6	58	25	2.5	n.t.	n.t.	17.3
L5	76	M	DLBCL, NOS	Lymph node	+	IVB	10,700	7,875	8.4	8.3	39	19	4.6	178	n.t.	9.0
L6	59	F	IVLBCL	Skin, lung	Not detected	IVB	4,900	2,793	9.0	20.5	46	8	8.9	408	306	8.2
L7	77	F	IVLBCL	Bone marrow	+	IVB	3,500	2,730	7.4	5.0	20	30	2.4	220	n.t.	3.0
L8	86	F	IVLBCL	Bone marrow	+	IVB	2,400	1,872	11.1	7.3	96	58	1.9	100	169	5.0
L9	56	M	ENKL	Liver	+	IVB	1,800	1,026	12.6	8.5	157	132	3.4	163	249	0.3
L10	62	F	PTCL, NOS	Lymph node	+	IVB	2,900	2,523	10.7	8.5	142	60	3.0	99	211	10.1
L11	65	F	PTCL, NOS	Skin	+	IVB	3,100	1,225	9.0	10.6	35	20	1.3	256	n.t.	1.1

ANC absolute neutrophil count; TG triglyceride; Fib fibrinogen; IVBCL intravascular B cell lymphoma; DLBCL, NOS diffuse large B cell lymphoma, not otherwise specified; ENKL extranodal NK cell lymphoma; PTCL, NOS peripheral T cell lymphoma, not otherwise specified; UNL upper normal limit; n.t. not tested

Table 4.

Clinical characteristics of patients with LAHS

Case	Splenomegaly	Hemophagocytosis	NCC (/μl)	Histiocyte (%)	HLH-2004	sIL-2R (U/ml)	Ferritin (ng/ml)	sIL-2R/ferritin
L1	+	+	11.0 × 104	1.0	5 (8)	9,221	2,613	3.52
L2	+	+	6.4 × 104	2.4	5 (8)	9,793	3,273	2.99
L3	+	+	Dry tap	4.0	5 (8)	12,569	2,861	4.39
L4	+	+	17.0 × 104	1.6	5 (8)	4,291	1,729	2.48
L5	+	+	5.5 × 104	0.2	6 (8)	36,938	1,184	31.19
L6	+	+	4.4 × 104	2.0	6 (8)	3,462	718	4.82
L7	+	+	6.0 × 104	3.0	6 (8)	11,536	707	16.31
L8	+	+	1.0 × 104	1.0	6 (8)	36,715	3,477	10.55
L9	+	+	2.8 × 104	0.8	5 (8)	3,588	4,923	0.72
L10	+	+	7.0 × 104	0.4	6 (8)	10,230	6,067	1.68
L11	+	+	2.8 × 104	1.0	5 (8)	9,620	619	15.54

NCC nuclear cell count

The median age of the benign disease-associated HLH group (Tables 1 and 2) was 43.6 years, ranging between 17 and 68 years. The etiologic subtypes were infection (pneumonia, n = 1; Epstein–Barr virus, n = 1; cytomegalovirus, n = 1; and malaria, n = 2), and autoimmune disorders (adult-onset Still’s disease (AOSD), n = 2). The underlying cause could not be determined in two patients (cases B1 and B5) in spite of tests being performed for the Epstein–Barr virus, cytomegalovirus, parvovirus, virus hepatitis (hepatitis A, B, and C), sepsis, autoimmune disorders, drugs, and malignancy. Both patients recovered with short-term immunosuppressive therapy (case B1, corticosteroid + cyclosporine; case B5, corticosteroid), and recurrences was not observed.

The median age of the LAHS group (Tables 3 and 4) was 72.0 years, ranging between 56 and 98 years. The most frequent histopathological subtype was intravascular large B cell lymphoma (IVLBCL), Asian variant (n = 6), and diffuse large B cell lymphoma (DLBCL), not otherwise specified (NOS) (n = 2), followed by peripheral T cell lymphoma (PTCL), NOS (n = 2), and extranodal NK/T cell lymphoma, nasal type (ENKL) (n = 1). All patients in the LAHS group were clinical stage IVB, and bone marrow involvement was observed in nine patients. According to the International Prognostic Index, all patients were categorized as high risk. Neither a distinct tumor mass nor apparent lymph node enlargement was noted in six patients (cases L1, L2, L4, L6, L7, and L8), and lymphoma was diagnosed by bone marrow examination in four out of six patients. One patient (case L2) was diagnosed with lymphoma by autopsy, and one patient (case L6) was diagnosed with lymphoma by transbronchial lung biopsy (TBLB) and random skin biopsy.

Laboratory findings

The laboratory findings of the initial presentation are summarized in Tables 1 and 2 (case B1-10, the benign disease-associated HLH group) and Tables 3 and 4 (case L1-11, the LAHS group). All our patients fulfilled the required criteria for the diagnosis of HLH. Although serum ferritin levels were under 1,000 ng/ml in four cases (cases L6, L7, L11, and B6), hemophagocytosis by activated macrophages was confirmed in the bone marrow.

One patient in the benign disease-associated HLH group (10 %) had anemia (Hb ≤ 10.0 g/dl), while seven patients (70 %) had thrombocytopenia (PLT ≤ 100,000/μl). Other findings of interest were increased levels of LDH, ferritin, CRP, and sIL-2R in all patients examined. One patient had hypofibrinogenemia (fibrinogen of ≤150 mg/dl), and two patients had hypertriglyceridemia (triglycerides of ≥265 mg/dl).

Seven patients in the LAHS group (63.6 %) had anemia (Hb ≤ 10.0 g/dl), while six patients (54.5 %) had thrombocytopenia (PLT ≤ 100,000/μl). LDH, CRP, ferritin, and sIL-2R levels were elevated in all patients. Although very high CRP was observed in two patients (cases L3 and L4), infection was not complicated in both these patients. Two patients had hypofibrinogenemia (fibrinogen of ≤150 mg/dl), and one patient had hypertriglyceridemia (triglycerides of ≥265 mg/dl).

Comparison of laboratory findings between LAHS and benign disease-associated HLH

A comparison of laboratory findings between the LAHS and disease-associated HLH groups is shown in Table 5. There were no significant differences in LDH or CRP levels (p = 0.53 and p = 0.94). Neutropenia and thrombocytopenia were more severe in the benign disease-associated HLH group (p = 0.045 and p = 0.045). Anemia was more severe in the LAHS group (p = 0.005). Liver enzymes in the benign disease-associated HLH were higher than those in the LAHS group. The mean sIL-2R levels were higher (p = 0.0031), and the mean ferritin levels were lower (p = 0.0031) in the LAHS group than those in the benign disease-associated HLH group, respectively (Table 5). Consequently, the mean serum sIL-2R/ferritin ratio of patients with LAHS was markedly higher than that of patients with benign disease-associated HLH (8.56 vs. 0.66, p = 0.0004) (Table 5).

Table 5.

Comparison of the laboratory findings of the two groups (benign disease-associated HLH and LAHS)

	Benign disease-associated HLH	Range	LAHS	Range	p value
	Mean ± SD		Mean ± SD
	n = 10		n = 11
WBC (×109/l)	4,050 ± 1,152	600–13,800	4,509 ± 799	1,800–10,700	NS
ANC (×109/l)	2,440 ± 1,170	189–12,765	3,119 ± 650	1,026–7,875	<0.05
Hb (g/dl)	11.8 ± 0.5	9.2–13.8	9.4 ± 0.5	7.4–12.6	<0.01
PLT (×109/l)	7.2 ± 1.1	4.2–13.9	10.8 ± 1.4	5.0–20.5	<0.05
AST (U/l)	1,161 ± 622	40–6,300	63.4 ± 14.2	20–157	<0.01
ALT (U/l)	904 ± 391	37–3,400	36.3 ± 10.9	8–132	<0.001
LDH (/UNL)	8.1 ± 3.2	1.4–32.3	3.6 ± 0.7	1.3–8.9	NS
CRP (mg/dl)	9.4 ± 2.9	0.4–23.6	9.0 ± 2.6	0.3–29.3	NS
sIL-2R (U/ml)	4,176 ± 677	2,162–8,657	13,451 ± 3,611	3,462–36,938	<0.005
Ferritin (ng/ml)	20,462 ± 9,330	882–100,000	2,561 ± 544	619–6,067	<0.005
sIL-2R/ferritin	0.66 ± 0.25	0.06–2.73	8.56 ± 2.79	0.72–31.1	<0.0005

UNL upper normal limit, NS not significant

Discussion

Secondary HLH presents in a number of different clinical contexts with various etiologic associations. Patients typically have concurrent infections/medical conditions that appear to trigger their HLH, such as infection, malignancy, or autoimmune disorders [1–3]. In this study, we presented 21 secondary HLH cases diagnosed at a single institution. The major etiology of our cases was lymphoma, followed by infection (EBV, CMV, malaria), and AOSD. AOSD is a systemic inflammation disorder of unknown origin characterized by spiking fever, rash, polyarthralgia, and hyperferritinemia. Macrophage activation syndrome (MAS) is a life-threatening complication of AOSD [9, 10]. Clinically, patients with MAS present with high fever, pancytopenia, hepatosplenomegaly, hepatic dysfunction, encephalopathy, coagulation abnormalities, and sharply increased levels of ferritin. As MAS is clinically similar to HLH, it is currently classified among the secondary forms of HLH [8]. It is difficult to distinguish an AOSD flare from HLH/MAS because HLH/MAS and AOSD share several clinical features [11]. Preliminary diagnostic guidelines have been presented for MAS, which consisted of laboratory and clinical criteria [7]. There were two cases of AOSD-associated HLH (cases B9 and B10) in this study, and both of them satisfied the diagnostic criteria of MAS.

A Japanese survey revealed that LAHS was a major subtype in adult-onset HLH cases and had a poor outcome [5]. LAHS accounted for 43 % of HLH patients older than 15 years of age and for 67 % of patients older than 60 years of age [5]. Approximately 46 % of patients with LAHS were associated with B cell lymphoma (B-LAHS), and approximately 32 % with NK/T cell lymphoma (NK/T-LAHS) [5]. The predominant histology of B cell tumors was DLBCL (15 %) and IVLBCL (14 %), while PTCL (12 %) and ENKL (11 %) were the major histologic subtypes noted among T/NK cell tumors [5]. Ishii et al. analyzed the outcome of a distinct subtype of HLH and showed that the 5-year overall survival rates were 48.2 % for B-LAHS, 12.2 % for NK/T-LAHS, 82.7 % for Epstein–Barr virus-HLH, 89.0 % for other infection-associated HLH, and 89.6 % for autoimmune-associated HLH [5]. The lack of mass formation and absence of apparent lymph node enlargement often delays the diagnosis of LAHS, which results in the progression of the disease and an unfavorable prognosis. LAHS, especially IVLBCL with HLH, develops rapidly, and a diagnostic delay contributes to fatal outcome. IVLBCL accounts for 0.9 % of all lymphomas in Japan (Okamoto et al. 2009) and is characterized by fever and hepatosplenomegaly without lymphadenopathy at initial presentation.

Tabata et al. reviewed 110 patients, including 57 LAHS cases and 53 benign disease-associated HLH cases in the literature, and demonstrated the important role of not only a high serum sIL-2R level (≥5,000 U/ml) but also a high sIL-2R/ferritin ratio (≥2.0) in the diagnosis of LAHS [6]. In addition, they evaluated the positive predictive values of parameters for LAHS. The positive predictive value (PPV) for LAHS of high sIL-2R (≥5,000 U/ml) was 81.0 %, and the PPV for LAHS of a high sIL-2R/ferritin ratio (≥2.0) was 85.2 % [6]. Moreover, the PPV of both parameters combined was 95.6 % [6]. They then proposed that the serum sIL-2R/ferritin ratio could be used as a useful marker to diagnosis of LAHS. However, variations in the normal ranges of sIL-2R and ferritin have been reported, depending on the various assays used in different laboratories. In addition, neither the clinical features of HLH patients nor the diagnostic criteria were shown in this study.

Therefore, we attempted to analyze the laboratory findings including parameters such as sIL-2R, ferritin, and sIL-2R/ferritin in the HLH patients diagnosed in our institution to verify this study. Our results showed that the level of sIL-2R was significantly higher (p = 0.0031) and the ferritin level was lower (p = 0.0031) in the LAHS group than that in the benign disease-associated HLH group. Consequently, the mean serum sIL-2R/ferritin ratio of patients with LAHS was significantly higher than that of patients with benign disease-associated HLH (p = 0.0004) (Table 5). In the LAHS group, a high serum sIL-2R level (≥5,000 U/ml) and high sIL-2R/ferritin ratio (≥2.0) were observed in 8 and 9 out of 11 patients, respectively. In contrast, cases with a high serum sIL-2R level and high sIL-2R/ferritin ratio in the benign disease-associated HLH group were only 2 and 1 out of 10 patients, respectively.

The clinical features of each case further revealed the usefulness of these parameters. For example, the underlying disease of HLH in case L2 (Tables 3 and 4) was not diagnosed until IVBCL was confirmed by autopsy. The sIL-2R level and sIL-2R/ferritin ratio at the diagnosis of HLH were as high as 9,793 U/ml and 2.99, respectively. In case L6 (Tables 3 and 4) without lymphadenopathy or the bone marrow infiltration of tumor cells, only TBLB and random skin biopsy confirmed the presence of IVLBCL with HLH. Although the sIL-2R level was relatively low (3,462 U/ml), the sIL-2R/ferritin ratio was as high as 4.82. On the other hand, the underlying cause of HLH in case B9 (Tables 1 and 2) was first suspected to be malignant lymphoma because of elevations in LDH, sIL-2R, and β2 microglobulin levels and abnormal uptakes by an enlarged spleen on FDG-PET/CT scanning. Six months after the diagnosis of HLH, the patient exhibited a typical rash and arthralgia and was diagnosed with AOSD. At the diagnosis of HLH, her sIL-2R level was less than 5,000 U/ml (4,733 U/ml), and sIL-2R/ferritin ratio was as low as 0.45. Thus, both of these parameters, especially the latter, appear to be useful for predicting the presence of lymphoma in the background of HLH.

The pathogenesis of secondary HLH is not as well understood as that of primary HLH. However, secondary HLH is also characterized by a marked elevation in the serum level of sIL-2R and ferritin, both of which are the parameters of diagnostic criteria [7]. Hyperferritinemia generally reflects the activation of macrophages in HLH, while elevated levels of sIL-2R reflect T cell activation [10–12]. Relatively high sIL-2R and relatively low ferritin levels in LAHS result in a markedly high sIL-2R/ferritin ratio, which ratio may indicate excessive T cell activation related to the activation of macrophages in LAHS.

In summary, we evaluated the laboratory findings of HLH patients in our institution and recognized the utility of the sIL-2R/ferritin ratio for diagnosing LAHS. A high sIL-2R/ferritin ratio strongly indicates the presence of underlying malignant lymphoma.